Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Name: Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
License: Public Domain

National Heart, Lung, and Blood Institute (NHLBI)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

cell

b-cell chronic lymphocytic leukemia, b-lymphocytic leukemia, chronic, chronic lymphocytic leukemia, leukemia, chronic lymphatic, leukemia, chronic lymphocytic, b-cell, leukemia, lymphocytic, chronic

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 349956
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.